Chan faces financing challenges in second term as WHO director-general

NewsGuard 100/100 Score

The expected re-appointment of Margaret Chan as the WHO's director-general "comes at a perilous moment for WHO," a Lancet editorial states. Although "WHO is in crisis" and "[r]escue is needed," the situation is not "a fair reflection of the director-general's performance," the editorial adds, noting several successes of her first term, including initiatives on women's and children's health and non-communicable diseases (NCDs).

However, "[n]one of this is to say that there have not been disappointments," the Lancet writes, adding that "[h]er leadership team has not been a success," and "sometimes one wishes for a sharper message, a stronger articulation of what WHO is for in the 21st century." The editorial concludes, "These matters can be addressed during a second term. But that term will depend on proper financing of WHO by its donors. And here Dr. Chan faces her greatest test of all" (1/14).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.